The role of blood markers in patients with endometrial cancer to assess the prognosis of disease.
- Conditions
- Health Condition 1: C541- Malignant neoplasm of endometrium
- Registration Number
- CTRI/2020/11/028943
- Lead Sponsor
- All India Institute of Medical Sciences New Delhi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Cases
All diagnosed cases of Endometrial Carcinoma
Ability to comply with the protocol.
Adequate cardiorespiratory, renal and liver functions and who are fit to undergo surgery.
Controls
Patients admitted for surgery for benign gynecological conditions (leiomyoma, uterovaginal prolapse, adenomyosis).
Endometrial histopathology of uterus and cervix proven negative for malignancy.
Ability to comply with the protocol.
Adequate cardiorespiratory, renal and liver functions and who are fit to undergo surgery.
Cases
•Patients who have already undergone surgical procedures for Endometrial carcinoma
•Patients known to have other malignancies
•History of hysterectomy, bilateral oophorectomy, or Lynch syndrome
•History of use of exogenous hormones
Controls
•Patients unwilling to participate in the study
•Patients known to have other malignancies
•History of hysterectomy, bilateral oophorectomy, or Lynch syndrome
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Serum levels of visfatin and adiponectin in patients with carcinoma endometrium and controls <br/ ><br>2.Serum levels of visfatin and adiponectin in patients with endometrial carcinoma who had deep myometrial invasion, grade 2/3 disease and lymph node involvement. <br/ ><br>3.Serum levels of visfatin and adiponectin in patients with endometrial carcinoma who had no or superficial myometrial invasion, grade 1 disease and without lymph node involvement. <br/ ><br>Timepoint: After 1 year <br/ ><br>
- Secondary Outcome Measures
Name Time Method 1.Visfatin adiponectin ratio (V:A ratio) in patients with carcinoma endometrium <br/ ><br>2.Visfatin adiponectin ratio (V:A ratio) in controls <br/ ><br>Timepoint: After 1 year